Press Releases

A comprehensive library of Ipsen media releases for investors and members of the press.

Explore more press releases

Topics

Period

recent search

Reset

Showing: 1 – 05 of 226 Press Releases

Ipsen mourns the passing of Henri Beaufour, a founding family Board member
01 December 2025

01 December 2025

Download Ipsen mourns the passing of Henri Beaufour, a founding family Board member
Ipsen mourns the passing of Henri Beaufour, a founding family Board member

 PARIS, FRANCE, 1 DECEMBER 2025 – It is with great sadness that Ipsen (Euronext: IPN; ADR: IPSEY) today announces that Henri Beaufour, Ipsen Board Member and a representative of the founding family, passed away on Friday, 28 November 2025.



Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
22 October 2025

22 October 2025

Download Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance

PARIS, FRANCE, 22 October 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year to date and the third quarter of 2025.


Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
22 October 2025

22 October 2025

Download Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline

PARIS AND MARSEILLE, FRANCE, 22 October 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImCheck Therapeutics,…


Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
22 September 2025

22 September 2025

Download Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III

PARIS, FRANCE, 22 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first aesthetic data (n=183) for glabellar lines with internally developed IPN10200, following Stage 1 of the multi-stage, ongoing Phase II LANTIC trial. Patients treated with IPN10200…


Your dedicated contacts
Stay updated